Lonza To Cut 200 In Hopkinton, Phase Out Plant
The parent group of Lonza Biologics will lay off most of its approximately 300 workers at its Hopkinton plant this year and gradually reduce operations there as part of cost reductions by the Switzerland-based pharmaceutical supplier.
Lonza said the reduction of roughly 200 employees at the South Street facility will take place gradually over the next several months. In an email response to questions, Lonza spokeswoman Melanie Disa said final staff-reduction plans are not complete yet.
Yesterday’s announcement came as the company announced financial results for the first half of the year. A statement from Lonza said the company will consolidate future microbial biologics work – which the Hopkinton site performs - in its largest plant in Visp, Switzerland. The company said it will honor all its obligations to existing customers served by the Hopkinton facility.
In recent years, Disa added, the Hopkinton plant has manufactured several commercial products and additional products for customers at various stages of clinical supply; it has also executed several research and development projects for customers around the world.
(Image credit: freedigitalphotos.net)
WBJ Web Partners
Most Recent
Most Recent
0 Comments